Font Size: a A A

Research On Audit Risk Of Reilated Party Transactions Of Listed Companies In Pharmaceutical Industry

Posted on:2019-06-06Degree:MasterType:Thesis
Country:ChinaCandidate:Y L PeiFull Text:PDF
GTID:2439330548975374Subject:Audit
Abstract/Summary:PDF Full Text Request
With the continuous development of China's economy and the increasingly close links between enterprises,there are not a few listed companies that use this kind of relationship between enterprises to manipulate profits.Because of the complexity of the related party relationships and transactions and concealment,the means of concealing the affiliated party transactions of listed companies is becoming more and more diversified,the fair of the affiliated party transactions greatly harm the interests of the broad masses of investors,which increased the difficulty of certified public accountants audit and audit risk.Moreover,as a pillar industry in China,the pharmaceutical industry has played an important role in promoting the development of the national economy,and the related party transactions are also large.Therefore,it is necessary to study the audit risk of related party transactions in the pharmaceutical industry.This paper reference the essential theoretical foundation of the domestic and foreign scholars,using descriptive statistics and case analysis with the combination of research methods for the pharmaceutical industry audit risk of related party transactions of listed companies is analyzed.Firstly,selected the pharmaceutical industry of Shanghai and shenzhen a-share listed company related party transactions data as sample,the sample data to carry on the related party transactions information disclosure status quo analysis,to find in the affiliated party transactions of listed companies information disclosure problems,thus find audit risk;Secondly,kangzhi pharmaceutical was selected as a specific case to identify and evaluate the audit risk of related party transactions in the pharmaceutical industry.Finally,specific risk control measures are proposed for the audit of related party transactions in the pharmaceutical industry,so as to provide a basis for the study of audit risk of related party transactions in other industries.Firm should pay attention to from level 3 review,pay attention to use analytical procedures,strengthen the construction of professional ethics of auditors to begin to control audit risk,only in this way of reducing audit risk to an acceptable low level,to maintain the interests of minority shareholders,to promote the healthy development of securities market in our country.
Keywords/Search Tags:Related party transaction, Pharmaceutical industry, Audit risk, Audit countermeasure
PDF Full Text Request
Related items